Claims

1. Use of an alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof for the manufacture of a medicament for the treatment and/or prevention of a disease or disorder of the nervous system.

2. Use of a vector comprising a nucleic acid sequence encoding an AAT protein for in the manufacture of a medicament for the treatment and/or prevention of a disease or disorder of the nervous system.

3. Use of a genetically modified cell comprising a nucleic acid sequence encoding an AAT protein for in the manufacture of a medicament for the treatment and/or prevention of a disease or disorder of the nervous system.

4. The use of any one of claims 1 to 3, wherein the disease or disorder of the nervous system is a disease or disorder of the peripheral nervous system.

5. The use of claim 4, wherein the disease or disorder of the peripheral nervous system is motor and sensory neuropathy of the peripheral nervous system.

6. The use of claim 5, wherein the sensory neuropathy of the peripheral nervous system is a hereditary motor and sensory neuropathy of the peripheral nervous system.

7. The use of claim 6, wherein the hereditary motor and sensory neuropathy of the peripheral nervous system is Charcot–Marie–Tooth disease or a symptom thereof, preferably at least one symptom selected from the group consisting of weakness in legs, ankles and/or feet, loss of muscle bulk in legs and/or feet, high foot arches, curled toes, decreased ability to run, difficulty lifting foot at the ankle, abnormal gait, frequent tripping or falling and decreased sensation or a loss of feeling in legs and/or feet.

8. The use of any one of claims 1 to 3, wherein the disease or disorder of the nervous system is an inflammatory disease or disorder of the nervous system.

9. The use of claim 8, wherein the inflammatory disease or disorder of the nervous system is a myeloid cell-mediated disease or disorder of the nervous system.

10. The use of any one of claims 1 to 3, 8 or 9, wherein the disease or syndrome of the nervous system is a disease or syndrome selected from the group of Parkinson's disease, dementia, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, and Huntington's disease.

11. The use of any one of claims 1 to 3 or 8 to 10, wherein the disease or disorder of the nervous system is at least one symptom of a disease or disorder of the nervous system selected from the group consisting of: tremor, memory loss, slurred speech, dizziness, change in vision and headache.

12. The use of any one of claims 1 or 4 to 11, wherein the AAT protein, a variant, an isoform and/or a fragment thereof is human plasma-extracted.

13. The use of any one of claims 1 or 4 to 11, wherein the alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof is recombinant alpha1-antitrypsin (rhAAT), a variant, an isoform and/or a fragment thereof.

14. The use of any one of claims 1 to 13, wherein the medicament comprises at least one pharmaceutical carrier.

15. The use of claim 14, wherein the pharmaceutical carrier is a blood-brain barrier permeability enhancer.

16. The use of any one of claims 1 to 15, wherein the medicament is formulated for intracerebral administration, intravenous injection, intravenous infusion, infusion with a dosator pump, inhalation nasal-spray, eye-drops, skin-patches, slow release formulations, ex vivo gene therapy or ex vivo cell-therapy.